Laboratory science.

AACR to showcase latest breakthroughs in cancer research The American Association for Tumor Research will showcase newsworthy research on clinical trials, epidemiology, immunology, epigenetics, laboratory science, and translational medicine at its Annual Conference, April 5-9. ‘This meeting may be the most important location for hearing the latest breakthroughs in cancer research both in the laboratory and in the clinic,’ stated AACR President Charles Sawyers, M.D., investigator at the Howard Hughes Medical Institute and chair of the Human being Oncology and Pathogenesis Plan at Memorial Sloan Kettering Cancer Center.Givens, B.A., Colby R. Ayers, M.S., Kyle E. Wedin, M.D., Ph.D., Ian J. Neeland, M.D., Ivan S. Yuhanna, Ph.D., Daniel R. Rader, M.D., James A. De Lemos, M.D., and Philip W. Shaul, M.D.: HDL Cholesterol Efflux Incident and Capability Cardiovascular Events A low level of high-density lipoprotein cholesterol is a significant independent risk element for atherosclerotic coronary disease.1 However, in randomized, controlled trials, high-dosage niacin or inhibitors of cholesteryl ester transfer proteins didn’t improve cardiovascular outcomes despite significantly increasing the HDL cholesterol level.2-5 Furthermore, genetic variants connected with HDL cholesterol levels tend to be not associated with coronary disease.